The U.S. Food and Drug Administration on Monday approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 and older, a boost for both the companies in the world's largest market for drugs....
Original Article: Regeneron/Sanofi wins U.S. approval for expanded use of skin drug